S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:PGNY

Progyny Stock Forecast, Price & News

$36.88
-1.36 (-3.56%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$36.82
$38.94
50-Day Range
$36.88
$64.37
52-Week Range
$36.82
$68.32
Volume
843,578 shs
Average Volume
919,763 shs
Market Capitalization
$3.34 billion
P/E Ratio
40.98
Dividend Yield
N/A
Beta
1.72
30 days | 90 days | 365 days | Advanced Chart
Receive PGNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.


Progyny logo

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PGNY
Fax
N/A
Employees
210
Year Founded
N/A

Sales & Book Value

Annual Sales
$344.86 million
Cash Flow
$0.19 per share
Book Value
$1.93 per share

Profitability

Net Income
$46.46 million
Pretax Margin
7.18%

Debt

Price-To-Earnings

Miscellaneous

Free Float
72,887,000
Market Cap
$3.34 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/23/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.47 out of 5 stars

Medical Sector

153rd out of 1,418 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

2nd out of 22 stocks

Analyst Opinion: 3.4Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Progyny (NASDAQ:PGNY) Frequently Asked Questions

Is Progyny a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Progyny stock.
View analyst ratings for Progyny
or view top-rated stocks.

How has Progyny's stock been impacted by COVID-19 (Coronavirus)?

Progyny's stock was trading at $22.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PGNY stock has increased by 65.3% and is now trading at $36.88.
View which stocks have been most impacted by COVID-19
.

When is Progyny's next earnings date?

Progyny is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for Progyny
.

How were Progyny's earnings last quarter?

Progyny, Inc. (NASDAQ:PGNY) released its quarterly earnings data on Thursday, November, 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.11. The business earned $122.30 million during the quarter, compared to the consensus estimate of $125.52 million. Progyny had a trailing twelve-month return on equity of 29.67% and a net margin of 18.96%. The firm's quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the company earned $0.05 EPS.
View Progyny's earnings history
.

What guidance has Progyny issued on next quarter's earnings?

Progyny updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share guidance of $0.510-$0.540 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.470. The company issued revenue guidance of $507 million-$514 million, compared to the consensus revenue estimate of $519.14 million.

What price target have analysts set for PGNY?

8 brokerages have issued 1-year price objectives for Progyny's stock. Their forecasts range from $53.00 to $81.00. On average, they expect Progyny's stock price to reach $68.00 in the next twelve months. This suggests a possible upside of 84.4% from the stock's current price.
View analysts' price targets for Progyny
or view top-rated stocks among Wall Street analysts.

Who are Progyny's key executives?

Progyny's management team includes the following people:

What is David Schlanger's approval rating as Progyny's CEO?

25 employees have rated Progyny CEO David Schlanger on Glassdoor.com. David Schlanger has an approval rating of 89% among Progyny's employees.

What other stocks do shareholders of Progyny own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progyny investors own include NVIDIA (NVDA), Alibaba Group (BABA), salesforce.com (CRM), Marvell Technology (MRVL), Alteryx (AYX), Micron Technology (MU), AbbVie (ABBV), Home Depot (HD), (HON) and Advanced Micro Devices (AMD).

When did Progyny IPO?

(PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

What is Progyny's stock symbol?

Progyny trades on the NASDAQ under the ticker symbol "PGNY."

Who are Progyny's major shareholders?

Progyny's stock is owned by a number of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (0.90%), Carnegie Capital Asset Management LLC (0.44%), Nordea Investment Management AB (0.28%), Russell Investments Group Ltd. (0.15%), Sumitomo Mitsui DS Asset Management Company Ltd (0.06%) and M&G Investment Management Ltd. (0.03%). Company insiders that own Progyny stock include Beth C Seidenberg, Cheryl Scott, David J Schlanger, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, Peter Anevski, Plc Glaxosmithkline and Robert Michael Floyd.
View institutional ownership trends for Progyny
.

Which institutional investors are selling Progyny stock?

PGNY stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui DS Asset Management Company Ltd, State of Alaska Department of Revenue, and PFG Advisors. Company insiders that have sold Progyny company stock in the last year include Cheryl Scott, David J Schlanger, Group Holdings (Sbs) Advis Tpg, Jennifer Bealer, Lisa Greenbaum, Mark S Livingston, Norman Payson, Perkins Caufield & Bye Kleiner, and Peter Anevski.
View insider buying and selling activity for Progyny
or view top insider-selling stocks.

Which institutional investors are buying Progyny stock?

PGNY stock was purchased by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Russell Investments Group Ltd., M&G Investment Management Ltd., Carnegie Capital Asset Management LLC, Nordea Investment Management AB, Crossmark Global Holdings Inc., FourThought Financial LLC, and Mountain Capital Investment Advisors Inc.
View insider buying and selling activity for Progyny
or or view top insider-buying stocks.

How do I buy shares of Progyny?

Shares of PGNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Progyny's stock price today?

One share of PGNY stock can currently be purchased for approximately $36.88.

How much money does Progyny make?

Progyny has a market capitalization of $3.34 billion and generates $344.86 million in revenue each year. The company earns $46.46 million in net income (profit) each year or $0.90 on an earnings per share basis.

How many employees does Progyny have?

Progyny employs 210 workers across the globe.

What is Progyny's official website?

The official website for Progyny is www.progyny.com.

Where are Progyny's headquarters?

Progyny is headquartered at 1359 BROADWAY, NEW YORK NY, 10018.

How can I contact Progyny?

Progyny's mailing address is 1359 BROADWAY, NEW YORK NY, 10018. The company can be reached via phone at 212-888-3124 or via email at [email protected].


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.